- Oragenics (OGEN +3.7%) and Intrexon (XON +0.5%) establish an Exclusive Channel Collaboration for the development and commercialization of "genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus."
- The companies intends to initially focus on a treatment for oral lesions associated with Behcet's. (PR)
- Previous: XON, OGEN announce results from lantibiotics testing
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs